Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Toa Eiyo describes new thiazolidine-based selective chymase inhibitors

June 5, 2000

INSIGHT study establishes once-daily Adalat as first-line therapy for higher risk hypertension

June 5, 2000

In vivo effects of BMS-189921 on NEP and ACE reported at hypertension meeting

June 1, 2000

Vasoactive diadenosine polyphosphates isolated and characterized by German investigators

June 1, 2000

Final results of ALLHAT published in JAMA

June 1, 2000

New activators of soluble guanylate cyclase especially useful for cardiovascular disorders

May 31, 2000

Losartan metabolite EXP-3174 does not possess antiarrhythmic properties

May 31, 2000

Azimilide and dofetilide highlighted at NASPE

May 31, 2000

Microbially produced NO inhibitor presented by Pola

May 30, 2000

EGF-genistein prevents restenosis in vivo

May 30, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...